{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T14:35:45Z","timestamp":1792420545930,"version":"4.5.0"},"reference-count":65,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T00:00:00Z","timestamp":1618185600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Mol. Biosci."],"abstract":"<jats:p>As of September 19, 2020, about 30 million people have been infected with the novel corona virus disease 2019 (COVID-19) globally, and the numbers are increasing at an alarming rate. The disease has a tremendous impact on every aspect of life, but one of the biggest, related to human health and medical sciences, is its effect on cancer. Nearly 2% of the total COVID-19 patients prior to May 2020 had cancer, and the statistics are quite frightening as the patient can be referred to as \u201cdoubly unfortunate\u201d to suffer from cancer with the added misery of infection with COVID-19. Data regarding the present situation are scarce, so this review will focus on the deadly duo of COVID-19 and cancer. The focus is on molecular links between COVID-19 and cancer as inflammation, immunity, and the role of angiotensin converting enzyme 2 (ACE2). Complications may arise or severity may increase in cancer patients due to restrictions imposed by respective authorities as an effort to control COVID-19. The impact may vary from patient to patient and factors may include a delay in diagnosis, difficulty managing both cancer therapy and COVID-19 at same time, troubles in routine monitoring of cancer patients, and delays in urgent surgical procedures and patient care. The effect of anti-cancer agents on the condition of cancer patients suffering from COVID-19 and whether these anti-cancer agents can be repurposed for effective COVID-19 treatment are discussed. The review will be helpful in the management of deadly duo of COVID-19 and cancer.<\/jats:p>","DOI":"10.3389\/fmolb.2021.643004","type":"journal-article","created":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T06:29:11Z","timestamp":1618208951000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":25,"title":["The Deadly Duo of COVID-19 and Cancer!"],"prefix":"10.3389","volume":"8","author":[{"given":"Vivek R.","family":"Bora","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bhoomika M.","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2021,4,12]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"965","DOI":"10.1038\/s43018-020-00120-5","article-title":"Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort.","volume":"1","author":"Albiges","year":"2020","journal-title":"Nat. Cancer"},{"key":"B2","year":"2020","journal-title":"International Agency for Research on Cancer."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1581","DOI":"10.3390\/cancers12061581","article-title":"Cancer and sars-cov-2 infection: diagnostic and therapeutic challenges.","volume":"12","author":"Allegra","year":"2020","journal-title":"Cancers"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e936","DOI":"10.1634\/theoncologist.2020-0213","article-title":"A practical approach to the management of cancer patients during the novel coronavirus disease 2019 (COVID \u221219) pandemic: an international collaborative group.","volume":"25","author":"Al-Shamsi","year":"2020","journal-title":"Oncologist"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.am2020-ct403","article-title":"Abstract CT403: outcome of cancer patients infected with COVID-19, including toxicity of cancer treatments","author":"Barlesi","year":"2020","journal-title":"Proceedings of the AACR Annual Meeting 2020 Cancer Research"},{"key":"B6","doi-asserted-by":"publisher","first-page":"2002672","DOI":"10.1183\/13993003.02672-2020","article-title":"Does chemotherapy reactivate SARS-CoV-2 in cancer patients recovered from prior COVID-19 infection?","volume":"56","author":"Bi","year":"2020","journal-title":"Eur. Respir. J."},{"key":"B7","doi-asserted-by":"publisher","first-page":"2771","DOI":"10.3748\/wjg.v20.i11.2771","article-title":"Challenges in managing hepatitis C virus infection in cancer patients.","volume":"20","author":"Borchardt","year":"2014","journal-title":"World J. Gastroenterol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"5045","DOI":"10.2147\/DDDT.S282252","article-title":"Repurposing anti-cancer drugs for COVID-19 treatment.","volume":"14","author":"Borcherding","year":"2020","journal-title":"Drug Des. Dev. Ther."},{"key":"B9","doi-asserted-by":"publisher","first-page":"1459","DOI":"10.1001\/jamaoncol.2020.2028","article-title":"COVID-19 in children with cancer in New York city.","volume":"6","author":"Boulad","year":"2020","journal-title":"JAMA Oncol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1007\/s41649-020-00118-2","article-title":"COVID-19 super-spreaders: definitional quandaries and implications.","volume":"12","author":"Cave","year":"2020","journal-title":"Asian Bioeth. Rev."},{"key":"B11","doi-asserted-by":"publisher","first-page":"5435","DOI":"10.1016\/j.vaccine.2013.09.001","article-title":"Immunologic consequences of chemotherapy for ovarian cancer: impaired responses to the influenza vaccine.","volume":"31","author":"Chu","year":"2013","journal-title":"Vaccine"},{"key":"B12","doi-asserted-by":"publisher","first-page":"783","DOI":"10.1158\/2159-8290.CD-20-0422","article-title":"Patients with cancer appear more vulnerable to SARS-CoV-2: a multicenter study during the COVID-19 outbreak.","volume":"10","author":"Dai","year":"2020","journal-title":"Cancer Discov."},{"key":"B13","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1056\/NEJMoa1014618","article-title":"Abiraterone and increased survival in metastatic prostate cancer.","volume":"364","author":"de Bono","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1038\/s43018-020-00122-3","article-title":"The immuno-oncological challenge of COVID-19.","volume":"1","author":"Derosa","year":"2020","journal-title":"Nat. Cancer"},{"key":"B15","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1200\/go.20.00097","article-title":"COVID-19 and cancer: lessons from a pooled meta-analysis.","volume":"6","author":"Desai","year":"2020","journal-title":"JCO Glob. Oncol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2020.04.026","article-title":"SARS-COV-2 infection in patients with cancer undergoing checkpoint blockade: clinical course and outcome.","volume":"133","author":"di Giacomo","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"B17","doi-asserted-by":"publisher","first-page":"102991","DOI":"10.1016\/j.critrevonc.2020.102991","article-title":"COVID 19 therapies and anti-cancer drugs: a systematic review of recent literature.","volume":"152","author":"di Lorenzo","year":"2020","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"750","DOI":"10.1016\/S1470-2045(20)30265-5","article-title":"Fewer cancer diagnoses during the COVID-19 epidemic in the Netherlands.","volume":"21","author":"Dinmohamed","year":"2020","journal-title":"Lancet Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1158\/2159-8290.CD-ND2020-006","article-title":"Cancer labs pivot to battle COVID-19.","volume":"10","year":"2020","journal-title":"Cancer Discov."},{"key":"B20","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1016\/j.ejca.2020.09.014","article-title":"Repurposing anticancer drugs for the management of COVID-19.","volume":"141","author":"El Bairi","year":"2020","journal-title":"Eur. J. Cancer"},{"key":"B21","doi-asserted-by":"publisher","first-page":"2605","DOI":"10.1161\/CIRCULATIONAHA.104.510461","article-title":"Effect of angiotensin-converting enzyme inhibition and angiotensin II receptor blockers on cardiac angiotensin-converting enzyme 2.","volume":"111","author":"Ferrario","year":"2005","journal-title":"Circulation"},{"key":"B22","doi-asserted-by":"publisher","first-page":"L52","DOI":"10.1152\/ajplung.00047.2018","article-title":"Inhibiting Bruton\u2019s tyrosine kinase rescues mice from lethal influenza-induced acute lung injury.","volume":"315","author":"Florence","year":"2018","journal-title":"Am. J. Physiol. Lung Cell. Mol. Physiol."},{"key":"B23","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1016\/S1470-2045(20)30314-4","article-title":"COVID-19 in patients with thoracic malignancies (TERAVOLT): first results of an international, registry-based, cohort study.","volume":"21","author":"Garassino","year":"2020","journal-title":"Lancet Oncol."},{"key":"B24","doi-asserted-by":"publisher","first-page":"105949","DOI":"10.1016\/j.ijantimicag.2020.105949","article-title":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial.","volume":"56","author":"Gautret","year":"2020","journal-title":"Int. J. Antimicrob. Agents"},{"key":"B25","doi-asserted-by":"publisher","first-page":"689","DOI":"10.1038\/s41416-020-0960-1","article-title":"COVID-19 and cancer research.","volume":"123","author":"Harris","year":"2020","journal-title":"Br. J. Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1637","DOI":"10.1038\/s41375-020-0836-7","article-title":"COVID-19 in persons with haematological cancers.","volume":"34","author":"He","year":"2020","journal-title":"Leukemia"},{"key":"B27","doi-asserted-by":"publisher","first-page":"497","DOI":"10.1016\/S0140-6736(20)30183-5","article-title":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.","volume":"395","author":"Huang","year":"2020","journal-title":"Lancet"},{"key":"B28","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ijmyco.2015.05.015","article-title":"Reactivation of pulmonary tuberculosis during cancer treatment.","volume":"4","author":"Jacobs","year":"2015","journal-title":"Int. J. Mycobacteriol."},{"key":"B29","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1200\/GO.20.00064","article-title":"Outcome of oncology patients infected with coronavirus.","volume":"6","author":"Jazieh","year":"2020","journal-title":"J. Glob. Oncol."},{"key":"B30","year":"2021","journal-title":"New Cases of COVID-19 In World Countries."},{"key":"B31","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1007\/s12195-020-00630-3","article-title":"The impact of COVID-19 on cancer risk and treatment.","volume":"13","author":"Jyotsana","year":"2020","journal-title":"Cell. Mol. Bioeng."},{"key":"B32","doi-asserted-by":"publisher","first-page":"813","DOI":"10.1007\/s00262-016-1810-0","article-title":"High immunosuppressive burden in cancer patients: a major hurdle for cancer immunotherapy.","volume":"65","author":"Kalathil","year":"2016","journal-title":"Cancer Immunol. Immunother."},{"key":"B33","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.ejps.2019.01.028","article-title":"Towards modern anticancer agents that interact with tubulin.","volume":"131","author":"La Regina","year":"2019","journal-title":"Eur. J. Pharm. Sci."},{"key":"B34","doi-asserted-by":"publisher","first-page":"102","DOI":"10.1016\/j.jpha.2020.03.001","article-title":"Molecular immune pathogenesis and diagnosis of COVID-19.","volume":"10","author":"Li","year":"2020","journal-title":"J. Pharm. Anal."},{"key":"B35","doi-asserted-by":"publisher","first-page":"335","DOI":"10.1016\/S1470-2045(20)30096-6","article-title":"Cancer patients in SARS-CoV-2 infection: a nationwide analysis in China.","volume":"21","author":"Liang","year":"2020","journal-title":"Lancet Oncol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.trsl.2020.04.007","article-title":"Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases.","volume":"220","author":"Magro","year":"2020","journal-title":"Transl. Res."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1040","DOI":"10.1016\/j.annonc.2020.04.479","article-title":"Androgen-deprivation therapies for prostate cancer and risk of infection by SARS-CoV-2: a population-based study (N = 4532).","volume":"31","author":"Montopoli","year":"2020","journal-title":"Ann. Oncol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1080\/0284186X.2017.1406668","article-title":"Interleukin-6 as one of the potential mediators of immune-related adverse events in non-small cell lung cancer patients treated with immune checkpoint blockade: evidence from a case report.","volume":"57","author":"Naqash","year":"2018","journal-title":"Acta Oncol."},{"key":"B39","year":"2020","journal-title":"Cancer Prevention Overview (PDQ<sup>\u00ae<\/sup>)\u2013Patient Version."},{"key":"B40","doi-asserted-by":"publisher","first-page":"2640","DOI":"10.1097\/QAD.0000000000002019","article-title":"Successful use of the potent enzyme inducer enzalutamide in a treatment-experienced HIV-positive male with prostate cancer.","volume":"32","author":"Nhean","year":"2018","journal-title":"AIDS"},{"key":"B41","first-page":"1","article-title":"Cancer facts & figures 2020.","year":"2020","journal-title":"CA Cancer J. Clin."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.3332\/ECANCER.2020.1047","article-title":"Cancer is associated with severe disease in COVID-19 patients: a systematic review and meta-analysis.","volume":"14","author":"Ofori-Asenso","year":"2020","journal-title":"Ecancermedicalscience"},{"key":"B43","doi-asserted-by":"publisher","first-page":"e000817","DOI":"10.1136\/esmoopen-2020-000817","article-title":"Prescreening for COVID-19 in patients receiving cancer treatment using a patient-reported outcome platform.","volume":"5","author":"Peeters","year":"2020","journal-title":"ESMO Open"},{"key":"B44","doi-asserted-by":"publisher","first-page":"270","DOI":"10.1038\/s41586-020-2012-7","article-title":"A pneumonia outbreak associated with a new coronavirus of probable bat origin.","volume":"579","author":"Peng","year":"2020","journal-title":"Nature"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1016\/S0140-6736(20)30691-7","article-title":"Immunosuppression for hyperinflammation in COVID-19: a double-edged sword?","volume":"395","author":"Ritchie","year":"2020","journal-title":"Lancet"},{"key":"B46","doi-asserted-by":"publisher","first-page":"784","DOI":"10.1038\/s43018-020-0104-9","article-title":"SARS-CoV-2 infection in the Italian Veneto region: adverse outcomes in patients with cancer.","volume":"1","author":"Rugge","year":"2020","journal-title":"Nat. Cancer"},{"key":"B47","doi-asserted-by":"publisher","first-page":"694","DOI":"10.1038\/s41416-020-0948-x","article-title":"Repurposing anticancer drugs for COVID-19-induced inflammation, immune dysfunction, and coagulopathy.","volume":"123","author":"Saini","year":"2020","journal-title":"Br. J. Cancer"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1425","DOI":"10.2217\/fon-2020-0369","article-title":"Coronavirus disease-2019 in cancer patients. A report of the first 25 cancer patients in a western country (Italy).","volume":"16","author":"Stroppa","year":"2020","journal-title":"Future Oncol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.annonc.2020.05.009","article-title":"Collateral damage: the impact on outcomes from cancer surgery of the COVID-19 pandemic.","volume":"31","author":"Sud","year":"2020","journal-title":"Ann. Oncol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1038\/s41577-020-0311-8","article-title":"The trinity of COVID-19: immunity, inflammation and intervention.","volume":"20","author":"Tay","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"B51","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1161\/ATVBAHA.119.312463","article-title":"Neutrophil extracellular traps: villains and targets in arterial, venous, and cancer-associated thrombosis.","volume":"39","author":"Th\u00e5lin","year":"2019","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"B52","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1002\/ijc.33213","article-title":"Cancer associates with risk and severe events of COVID-19: a systematic review and meta-analysis.","volume":"148","author":"Tian","year":"2020","journal-title":"Int. J. Cancer"},{"key":"B53","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1182\/BLOOD.2020006288","article-title":"The BTK inhibitor ibrutinib may protect against pulmonary injury in COVID-19 infected patients.","volume":"135","author":"Treon","year":"2020","journal-title":"Blood"},{"key":"B54","doi-asserted-by":"publisher","first-page":"02068","DOI":"10.1016\/j.ctrv.2020.102068","article-title":"SARS-CoV-2 and cancer: are they really partners in crime?","volume":"89","author":"van Dam","year":"2020","journal-title":"Cancer Treat. Rev."},{"key":"B55","doi-asserted-by":"publisher","first-page":"1752","DOI":"10.1111\/jth.14828","article-title":"Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): a case series.","volume":"18","author":"Wang","year":"2020","journal-title":"J. Thromb. Haemost."},{"key":"B56","year":"2020","journal-title":"WHO Director-General\u2019s Opening Remarks at the Media Briefing on COVID-19 - 11 March 2020."},{"key":"B57","year":"2021","journal-title":"Coronavirus Disease (COVID-19) Pandemic."},{"key":"B58","doi-asserted-by":"publisher","first-page":"e180","DOI":"10.1016\/S1470-2045(20)30150-9","article-title":"Risk of COVID-19 for patients with cancer.","volume":"21","author":"Xia","year":"2020","journal-title":"Lancet Oncol."},{"key":"B59","doi-asserted-by":"publisher","DOI":"10.2139\/ssrn.3527420","author":"Yang","year":"2020","journal-title":"Cell Pyroptosis, A Potential Pathogenic Mechanism of 2019-nCoV Infection."},{"key":"B60","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1016\/S2213-2600(20)30079-5","article-title":"Clinical course and outcomes of critically ill patients with SARS-CoV-2 pneumonia in Wuhan, China: a single-centered, retrospective, observational study.","volume":"8","author":"Yang","year":"2020","journal-title":"Lancet Respir. Med."},{"key":"B61","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1002\/1096-9071(200011)62:3<299::AID-JMV1<3.0.CO;2-0","article-title":"Frequency of hepatitis B virus reactivation in cancer patients undergoing cytotoxic chemotherapy: a prospective study of 626 patients with identification of risk factors.","volume":"62","author":"Yeo","year":"2000","journal-title":"J. Med. Virol."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.3892\/ijo.2015.2851","article-title":"The effectiveness of an anti-human IL-6 receptor monoclonal antibody combined with chemotherapy to target colon cancer stem-like cells.","volume":"46","author":"Ying","year":"2015","journal-title":"Int. J. Oncol."},{"key":"B63","doi-asserted-by":"publisher","first-page":"1108","DOI":"10.1001\/jamaoncol.2020.0980","article-title":"SARS-CoV-2 transmission in patients with cancer at a tertiary care hospital in Wuhan, China.","volume":"6","author":"Yu","year":"2020","journal-title":"JAMA Oncol."},{"key":"B64","doi-asserted-by":"publisher","first-page":"104960","DOI":"10.1016\/j.phrs.2020.104960","article-title":"Discovery of the FDA-approved drugs bexarotene, cetilistat, diiodohydroxyquinoline, and abiraterone as potential COVID-19 treatments with a robust two-tier screening system.","volume":"159","author":"Yuan","year":"2020","journal-title":"Pharmacol. Res."},{"key":"B65","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.ijid.2020.07.029","article-title":"Comorbidities and the risk of severe or fatal outcomes associated with coronavirus disease 2019: a systematic review and meta-analysis.","volume":"99","author":"Zhou","year":"2020","journal-title":"Int. J. Infect. Dis."}],"container-title":["Frontiers in Molecular Biosciences"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2021.643004\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,4,12]],"date-time":"2021-04-12T06:29:14Z","timestamp":1618208954000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmolb.2021.643004\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,4,12]]},"references-count":65,"alternative-id":["10.3389\/fmolb.2021.643004"],"URL":"https:\/\/doi.org\/10.3389\/fmolb.2021.643004","relation":{},"ISSN":["2296-889X"],"issn-type":[{"value":"2296-889X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,4,12]]},"article-number":"643004"}}